Silence Therapeutics (SLN) Operating Leases (2023 - 2026)

Silence Therapeutics (SLN) posted Operating Leases of $43000.0 for Q1 2026, down 39.44% sequentially from $71000.0 in Q4 2025.

Silence Therapeutics (SLN) Operating Leases (2023 - 2026) Analysis & Trends

Silence Therapeutics has reported Operating Leases for 3 years, with the latest figure at $43000.0 in Q1 2026.

Quarterly Operating Leases changed N/A year-over-year to $43000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43000.0 (changed N/A YoY) and the FY2025 annual result came in at $71000.0, changed N/A from the prior year.
Operating Leases fell to $43000.0 in Q1 2026 per SLN's latest filing, from $71000.0 in the prior quarter.
Over five years, Operating Leases peaked at $115427.1 in Q4 2023 and troughed at $43000.0 in Q1 2026.
A 3-year average of $81606.8 and a median of $84000.0 in 2025 frame the typical range for Operating Leases.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Silence Therapeutics	648.22 Mn	576.12 Mn	-

Download Data